The 2023 Intergenerational Report has reaffirmed the longstanding government view of investment in new therapeutic technologies as a 'cost' and that it will be the biggest driver of rising health costs.
IGR reinforces the isolation of health spending as a 'cost' to be managed
August 25, 2023 Latest NewsBioPharmaNews of the Day
Latest Video
New Stories
-
A scrapped website, almost $100 million, and the politics of what really matters
November 23, 2025 - - Latest News -
Mesoblast to launch pivotal adult trial for cell therapy in severe steroid-refractory GVHD
November 22, 2025 - - Australian Biotech -
Syntara launches Phase 2 trial aiming to teduce transfusion burden in myelodysplastic syndromes
November 22, 2025 - -
Alterity Therapeutics chairman reflects on two decades of progress as company enters new era
November 22, 2025 - - BioPharma -
Treasurer blocks US takeover of Mayne Pharma on national interest grounds
November 22, 2025 - - Latest News -
If the system properly applied results in harm, then the problem is worse than we think
November 20, 2025 - - Latest News -
Silence in response to unethical processes and outcomes is itself unethical
November 20, 2025 - - Latest News
